Markets Nosedive

A broker works while sitting in front of a screen displaying live stock quotes on the floor of a trading firm in Mumbai May 23, 2013. REUTERS/Vivek Prakash

Sensex loses 388 points, Nifty ends below 6,000 on Fed, China concerns

The Nifty posted its biggest percentage fall in a year on Thursday, as the prospect of an end to the U.S. stimulus programme and a weak China manufacturing survey sparked concerns foreign investors would end their recent buying spree.  Full Article 

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

RBI's May Review

RBI's May Review

Subbarao overrules panel view on rate action in May.  Full Article 

SBI Earnings

SBI Earnings

State Bank of India Q4 profit falls, shares drop.  Full Article | Related Story 

Bernanke Impact

Bernanke Impact

U.S. Fed enters delicate new phase of communication  Full Article | Column 

Subsidy Compensation

Subsidy Compensation

Government to pay state-run fuel retailers $8.1 billion in Q4 oil subsidy.  Full Article 

Ranbaxy Accusation

Ranbaxy Accusation

Daiichi Sankyo accusation "false and baseless": Singhs  Full Article 

Tata Steel Results

Tata Steel Results

Tata Steel reports loss on Europe weakness.  Full Article 

FDA Woes

FDA Woes

Wockhardt says FDA alert affects potential sales of $100 million.  Full Article 

Goldman Safeguards

Goldman Safeguards

Battle-scarred Goldman CEO unveils safeguards to avoid mistakes  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

India's Biocon sees oral insulin partner by March

Stocks

   

Wed Nov 23, 2011 3:11pm IST

(For other news from the Reuters India Investment Summit, click here)

BANGALORE Nov 23 (Reuters) - Biocon Ltd, India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive said on Wednesday .

"We are in advanced discussions with potential partners," Biocon's Managing Director Kiran Mazumdar-Shaw told the Reuters India Investment Summit in Bangalore.

In January, Biocon had said it was looking for a partner after its oral insulin, IN-105, failed to meet the main goal of an Indian late-stage trial in patients with type-2 diabetes.

Mazumdar-Shaw, however, declined to name any potential partners.

She also said the planned IPO of its contract research organisation, Syngene, was on track.

(For summit blog: blogs.reuters.com/summits/)

(For more on the Reuters India Investment Summit, see ) (Reporting by Anand Basu, Jochelle Mendonca and Aftab Ahmed in Bangalore. Editing by Sriraj Kalluvila, Saumyadeb Chakrabarty)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.